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ABSTRACT 
Background:  Krill  powder,  consisting  of  both  lipids  and  proteins,  has  been  reported  to 
modulate hepatic lipid catabolism in animals. Fish protein hydrolysate diets have also been 
reported to affect lipid metabolism and to elevate bile acid (BA) level in plasma. BA interacts 
with a number of nuclear receptors and thus affects a variety of signaling pathways, including 
very  low  density  lipoprotein  (VLDL)  secretion.  The  aim  of  the  present  study  was  to 
investigate whether a krill protein hydrolysate (KPH) could affect lipid and BA metabolism 
in mice.  
 
Method: C57BL/6 mice were fed a high-fat (21%, w/w) diet containing 20% crude protein 
(w/w) as casein (control group) or KPH for 6 weeks. Lipids and fatty acid composition were 
measured  from  plasma,  enzyme  activity  and  gene  expression  were  analyzed  from  liver 
samples, and BA was measured from plasma.  
 
Results:  The  effect  of  dietary  treatment  with  KPH  resulted  in  reduced  levels  of  plasma 
triacylglycerols (TAG) and non-esterified fatty acids (NEFAs). The KPH treated mice had 
also  a  marked  increased  plasma  BA  concentration.  The  increased  plasma  BA  level  was 
associated with induction of genes related to membrane canalicular exporter proteins (Abcc2, 
Abcb4) and to BA exporters to blood (Abcc3 and Abcc4). Of note, we observed a 2-fold 
increased nuclear farnesoid X receptor (Fxr) mRNA levels in the liver of mice fed KPH. We 
also  observed  increased  activity  of  the  nuclear  peroxiosme  proliferator-activated  receptor 
alpha (PPARα) target gene carnitine plamitoyltransferase 2 (CPT-2).  
 
Conclusion: The KPH diet showed to influence lipid and BA metabolism in high-fat fed 
mice.  Moreover,  increased  mitochondrial  fatty  acid  oxidation  and  elevation  of  BA 
concentration may regulate the plasma level of TAGs and NEFAs.  Functional Foods in Health and Disease 2013; 3(11):428-440                                                   Page 429 of 440 
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INTRODUCTION 
Bile acids (BA), essential components for solubilization of dietary fats, are synthesized in the 
liver from cholesterol. After synthesis, they are secreted across the canalicular membrane into 
the biliary tree and finally end up in the gall bladder. From the gall bladder the BAs are 
drained into the small intestine, reabsorbed by entrocytes and secreted into portal vein in 
order to be returned to the liver to complete the enterohepatic cycle. 
BAs interact with a number of nuclear receptors to stimulate a variety of signalling 
pathways. One of these receptors is the nuclear receptor farnesoid X receptor (FXR). The 
main physiological role of FXR is to maintain the BA homeostasis, and activation of FXR by 
BAs will regulate genes encoding proteins involved in the enterohepatic cycle. As BAs are 
reported to reduce plasma and liver triacylglycerol (TAG) level in animals [1, 2], this implies 
that FXR also play a role in the control of lipoprotein metabolism and in the secretion of very 
low  density  lipoprotein  (VLDL)  TAG  lipoprotein  fractions.  Further,  FXR  also  controls 
plasma TAG levels by activating the nuclear peroxiosme proliferator-activated receptor alpha 
(PPARα)  gene  [3].  PPARα  is  reported  to  induce  genes  encoding  enzymes  involved  in 
mitochondrial and peroxiosmal fatty acid oxidation (reviewed in [4]), and studies have shown 
that modulation of the fatty acid oxidation capacity is important in regulation of the TAG 
concentrations in serum and liver (reviewed in [5, 6]).  
High plasma TAG concentration is a characteristic feature of the metabolic syndrome, 
and  our  recent  findings  suggest  that  the  hypotriacylglyceridemic  property  of  PPARα 
activation  is  primary  due  to  effects  on  TAG  synthesis  and  on  mitochondrial  fatty  acid 
oxidation.  Abnormalities  in  insulin  signaling  have  also  been  found  associated  with  the 
metabolic syndrome, and interestingly, glucose metabolism also seems to be regulated by 
BAs and FXR activation (reviewed in [7, 8]). Furthermore, there is an increasing body of 
evidence  that  PPARα  does  not  only  regulate  lipid  metabolism,  but  also  the  amino  acid 
metabolism [9, 10]. 
The beneficial health effect of dietary krill intake has now been found in a limited 
number  of  studies.  The  hypotriacylglycerolemia  has  been  attributed  mostly  to  a  greater 
proportion of n-3 polyunsaturated fatty acids (PUFAs) in the phospholipid fraction of krill oil 
[11, 12]. Recently, we reported that krill powder, which contains approximately 40% protein 
(w/w) and 60% fat, increased liver lipid catabolism in tumor necrosis factor alpha (TNFα) 
transgenic mice fed a high-fat diet [13]. Thus, the hypolipidemic effect of dietary krill extract 
could be due to the oil and/or the protein content.  It has been found that a krill peptide 
showed blood-pressure lowering effects in animals [14], and a water-soluble extract of krill 
prevented TAG accumulation in adipocytes in culture via suppression of PPARα activity 
[15]. 
In the present study, we investigated whether the dietary water-soluble protein krill 
protein hydrolysate (KPH) was able to affect hepatic lipid and BA metabolism, and to lower 
plasma TAG levels in mice fed a high-fat diet for 6 weeks. We found that mice fed KPH 
displayed  increased  mitochondrial  fatty  acid  oxidation  capacity  and  lower  plasma  TAG 
concentration. Moreover, KPH-treated mice had a 16-fold higher fasting plasma BA levels 
than mice fed casein. 
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Animals and diets 
Male  C57BL/6  mice  were  used  (Taconic,  Germantown,  USA).  The  experiments  were 
performed in accordance with, and under the approval of, the Norwegian State Board for 
Biological Experiments, the Guide for the Care and Use of Laboratory Animals, and the 
Guidelines of the Animal Welfare Act. Mice aged between 6 and 8 weeks were  random 
divided into a experimental  (n = 6) and control (n = 9) group, and housed in pairs in open 
cages with constant temperature (22 ± 2°C) and humidity (55 ± 5 %). They were exposed to a 
12 h light-dark cycle and had unrestricted access  to  tap water and food. The mice were 
acclimatized under these conditions with standard chow for one week prior the start of the 
experiment. The animals weighed 27 ± 2 g at baseline, and there was no statistical difference 
in the weight between the groups (data not shown). 
  Mice were fed ad libitum for 6 weeks on a high-fat control diet or a high-fat KPH 
supplemented diet. The diets contained 20% (w/w) crude protein (N x 6,25) in the form of 
bovine milk casein (Dyets Inc., Bethlehem, PA, USA) or as the water-soluble protein KPH 
(Olympic Seafood AS, Myrvaag, Norway) (>70% with a molecular weight <1000 Da). All 
diets contained 21% (w/w) fat consisting of lard (19%, a generous gift from Ten Kate Vetten 
BV, Musselkanaal, Netherlands), and soy oil (2%, Dyets Inc.). The other constituents of the 
diets were cornstarch, dyetrose, sucrose, fiber, AIN-93G mineral mix, AIN-93 vitamin mix, 
L-Cysteine, Choline bitartrate (all from Dyets  Inc.), and tert-Butyl-hydroquinone (Sigma-
Aldrich Norway AS, Oslo, Norway). The nutrition composition of the experimental diets is 
described in Table 1, and the amino acid composition of casein and KPH is given in Table 2. 
  After  6  weeks  of  diet  treatment,  the  mice  were  anaesthetized  under  non-fasting 
conditions by inhalation of 2% isoflurane (Schering-Plough, Kent, UK). Blood was collected 
by aortic puncture with 7.5% EDTA and immediately chilled on ice for a minimum of 15 
minutes. The samples were centrifuged and plasma was stored at -80C prior to analysis. 
Parts of the liver were chilled on ice and used for enzyme activities, and the rest were freeze-
clamped and stored at -80C until further analysis.  
 
Plasma lipids and fatty acid composition 
Plasma lipids were extracted according to Bligh and Dyer [16], evaporated under nitrogen, 
and  redissolved  in  isopropanol  before  analysis.  Lipids  from  plasma  were  then  measured 
enzymatically on a Hitachi 917 system (Roche Diagnostics GmbH, Mannheim, Germany), 
using  the  triacylglycerol  (GPO-PAP)  and  cholesterol  (CHOD-PAP)  kit    from  Roche 
Diagnostics, and the  non-esterified fatty acid (NEFA) and phospholipid kit (phospholipids 
FS) from DiaSys (Diagnostic Laboratories GmbH, Holzheim, Germany).  
 
Table 1. Composition of the experimental diets* 
Macronutrients  Control (g/kg diet)  KPH (g/kg diet) 
Casein  224,7   
KPH    266,7 
Soybean oil  20  20 
Lard  190  190 
Cornstarch  90  90 
Dyetrose  132  132 
Sucrose  100  100 Functional Foods in Health and Disease 2013; 3(11):428-440                                                   Page 431 of 440 
Fiber  50  50 
Micronutrients     
AIN-93G-MX  mineral 
mix 
35  35 
AIN-93VX  vitamin 
mix 
10  10 
L-cystine  3  3 
Choline bitartrate  2,5  2,5 
Tert-Butyl-
hydroquinone 
0,014  0,014 
KPH, krill protein hydrolysate. 
 
*The diets were isonitrogenous and isoenergetic, and contained 20 g of crude protein/100 g 
of diet. KPH consisted of 75% protein and 3% fat; casein consisted of 89% protein and 0,8% 
fat.  
   
Table 2. Amino acid composition in casein and krill protein hydrolysate 
 
Amino acids  AA  Casein 
(g/100 g protein) 
KPH  
(g/100 g protein)  
Aspartic acid  ASP  7,28  8,17 
Glutamic acid  GLU  22,00  12,02 
Serine  SER  5,44  3,45 
Glycine  GLY  1,80  5,67 
Arginine  ARG  3,25  8,29 
Threonine  THR  4,05  3,26 
Alanine  ALA  2,92  6,35 
Proline  PRO  10,48  8,03 
Tyrosine  TYR  4,22  5,36 
Valine  VAL  6,23  4,56 
Methionine  MET  2,58  2,88 
Isoleucine  ILE  4,85  4,84 
Leucine  LEU  9,08  8,20 
Phenylalanine  PHE  5,16  4,27 
Lysine  LYS  7,88  7,68 
Histidine  HIS  2,76  0,00 
Taurine  TAU  0,00  6,97 
Methionine/Glycine  MET/GLY  1,43  0,51 
Lysine/Arginine  LYS/ARG  2,43  0,93 
 KPH, krill protein hydrolysate. 
     
Plasma bile acid measurement 
BA from plasma were measured enzymatically on a Roche Modular P chemistry analyzer 
(Roche  Diagnostica),  using  the  BA  kit  (Total  Bile  Acid  Assy  Kit,  05471605001)  from 
Diazyme (Diazyme Laboratories, Gregg, USA).  Functional Foods in Health and Disease 2013; 3(11):428-440                                                   Page 432 of 440 
Hepatic enzyme activities                     
The livers were homogenized and a post-nuclear fraction was prepared as described earlier 
[17]. The activities of carnitine palmitoyltransferase 1 (CPT-1a, EC number 2.3.1.21) and 
carnitine  plamitoyltransferase  2  (CPT-2,  EC  number  2.3.1.21),  acyl-CoA  oxidase  1, 
palmitoyl (ACOX1, EC number 1.3.3.6), glycerol-3-phosphate acyltransferase (GPAT, EC 
number 2.3.1.15) and fatty acid synthase (FASN, EC number 2.3.1.85) were measured in the 
post-nuclear fraction as described by Skorve et al.[18]. 
 
Hepatic gene expression 
Total cellular RNA was purified from frozen liver samples, and cDNA was produced as 
previously described [19]. Real-time PCR was performed with Sarstedt 384 well multiply-
PCR Plates (Sarstedt  Inc., Newton, NC, USA) on the following genes, using probes and 
primers from Applied Biosystems: ATP-binding cassette, sub-family C, member 2 (Abcc2, 
Mm00496899_m1),  ATP-binding  cassette,  sub-family  C,  member  3  (Abcc3, 
Mm00551550_m1),  ATP-binding  cassette,  sub-family  C,  member  4  (Abcc4, 
Mm01226381_m1),  ATP-binding  cassette,  sub-family  B,  member  1b  (Abcb1b, 
Mm00440736), ATP-binding cassette, sub-family B, member 4 (Abcb4, Mm00435630_m1), 
ATP-binding  cassette,  sub-family  B,  member  11  (Abcb11,  Mm00445168),  bile  acid 
Coenzyme A:amino acid  N-acyl  transferase (Baat, Mm00476075_m1),  cytochrome P450, 
family  7,  sub-family  A,  polypeptide  1  (Cyp7a1,  Mm00484152_m1),  farnesyl  X  receptor 
(Nr1H4, Mm00436419),  solute carrier family 10, member 1 (Slc10a1, Mm00441421_m1) 
and    solute  carrier  organic  anion  transporter  family,  member  1b2  (Slco1b2, 
Mm00451510_m1). Four different reference genes were included: 18S (Kit-FAM-TAMRA 
(Reference  RT-CKFT-18s))  from  Eurogentec,  Belgium,  glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh, Mm99999915_g1) from Applied Biosystems, TATA box binding 
protein (Tbp, AX-041188-00) and hypoxanthine guanine phosphoribosyl transferase (Hprt1, 
AX-045271-00) from Thermo Fisher Scientific. Data normalized to 18S rRNA are presented. 
 
Statistical analysis 
Data sets were analyzed using Prism Software (Graph-Pad Software, version 6, San Diego, 
CA) to determine statistical significance. The results are reported as means per group with 
their  standard  deviations  (SD).  Due  to  the  low  number  of  observations  in  each  group, 
nonparametric  statistical  test  were  used.  Mann-Whitney  test  was  performed  to  evaluate 
statistical differences between groups, and Wilcoxon signed-rank test was performed when 
comparing matched pairs. P-values < 0.05 were considered significant. 
 
RESULTS 
Growth of mice fed krill protein hydrolysate 
The average body weight in mice fed KPH decreased slightly over the test period (-2,3 ± 2,3 
g, non significant.), whereas the mice fed casein gained weight (8,2 ± 4,0 g, p = 0,004), 
resulting in a significant difference in change in weight between the groups over the period (p 
= 0,0004) (Fig. 1a-c).  The feed  consumption was  significantly higher in  the KPH group 
relative to the casein fed mice (p = 0,01) (Fig.1d). Further, the liver:body weight index was 
significantly lower in the KPH mice than in control (4,1 ± 0,4 % in KPH vs. 4,7 ± 0,4 % in 
control, p = 0,01) (Fig.1e). 
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Figure 1. Body weight gain are reduced in mice fed a krill protein hydrolysate-based diet  
Body weight gain in (a) the krill protein hydrolysate (KPH) group compared to (c) control (b) in male C57BL/6 
mice. Food intake was measured as average intake between day 5-7, and day 17-19 (d). The liver:body weight 
index (e) after six week of high-fat feeding containing casein or KPH. n = 6 for KPH groups and n = 9 for 
control groups, except for measurements of food intake (d), in which n = 4 for KPH group and n = 6 for control. 
Data  in  (c-e)  are  presented as  mean  ±  SD.  *  Denote  significant  difference:  Mann-Whitney  test;  Wilcoxon 
signed-rank test (* = p < 0,05; ** = p < 0,01; *** = p < 0,001). KPH, krill protein hydrolysate; ns, non-
significant. 
 
Reduced plasma lipids by feeding krill protein hydrolysate                    
The fasting plasma levels of TAGs, phospholipids and NEFAs were significantly reduced in 
the KPH treated mice compared to control (p = 0,0007; p = 0,03; p = 0,03, respectively) (Fig. 
2a-c). No difference was found in total plasma cholesterol (Fig. 2d). 
 
Hepatic enzyme activities 
Plasma  TAG  levels  are  determined  by  a  balance  between  hepatic  TAG  synthesis  and 
secretion on one hand, and plasma TAG clearance on the other. Moreover, the hepatic fatty 
acid oxidation capacity will regulate the VLDL synthesis and secretion. Interestingly, we 
found that the activity of PPAR-α targeted gene CPT-2 was stimulated in KPH fed mice Functional Foods in Health and Disease 2013; 3(11):428-440                                                   Page 434 of 440 
compared to control (p = 0,015) (Fig. 3a). Higher activity of other PPAR-α targeted genes, 
ACOX1 (p = 0,09) (Fig. 3b) and CPT-1 (in both absence and presence of malonyl-CoA), was 
also found in KPH relative to casein fed mice, but the differences did not reach statistical 
significance (CPT-1 with malonyl-CoA, p = 0,07; without malonyl-CoA, p = 0,15) (Fig. 3c). 
Hepatic TAG biosynthesis and lipogenesis seemed to be unaffected by KPH treatment as the 
activities of GPAT and FAS were similar in KPH treated mice compared to controls (Fig. 3d, e). 
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Figure 2. Krill protein hydrolysate reduces fasting plasma triacylglycerol 
Concentrations of (a) triacylglycerol (TAG), (b) phospholipids, (c) non-esterified fatty acids (NEFA) and (d) 
cholesterol in plasma of fasted  male C57BL/6  mice fed high-fat diets containing casein or KPH.  Data are 
presented as mean ± SD, n = 6 for KPH groups and n = 8 for control groups. * Denote significant difference: 
Mann-Whitney test (* = p < 0,05; *** = p < 0,001). KPH, krill protein hydrolysate; ns, non-significant; TAG, 
triacylglycerol; NEFA, non-esterified fatty acid. 
 
Plasma bile acid and hepatic genes of the enterohepatic cycle            
It  is  reported  that  BAs  have  the  potential  to  reduce  plasma  TAG  levels  [1,  2,  8,  20]. 
Therefore, it was of interest to note that KPH treatment increased the plasma BA level a 16-
fold compared to mice fed casein (Fig. 4).  
BAs are synthesized in the liver from cholesterol. The expression of the rate-limiting 
enzyme in this synthesis, Cyp7a1, was up-regulated in the liver of mice fed KPH. However, it 
did  not  reach  statistical  significance  (p  =  0,06)  (Fig.  5a).  After  BA  is  synthesized,  it  is 
conjugated with glycine and taurine [8, 21]. Gene expression of Baat, responsible for this 
conjugation, was not affected by KPH treatment compared to casein treated animals (Fig. 
5b). The gene expression of Fxr however, important in maintaining the BA homeostasis, was 
induced in KPH (p = 0,002) (Fig. 5c).  Functional Foods in Health and Disease 2013; 3(11):428-440                                                   Page 435 of 440 
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Figure 3. The effect of krill protein hydrolysate on hepatic enzyme activity  
Hepatic activities of (a) CPT-2, (b) ACOX1, (c) CPT-1, (d) GPAT, and (e) FAS in male C57BL/6 mice fed 
high-fat  diets  containing  casein  or  KPH.  Data  are  presented  as  mean  ±  SD,  n  =  6.  *  Denote  significant 
difference:  Mann-Whitney  test  (p  <  0,05).  ACOX1,  acyl-CoA  oxidase  1,  palmitoyl;  CPT-1,  carnitine 
plamitoyltransferase 1; CPT-2, carnitine plamitoyltransferase 2; FAS, fatty acid synthase; GPAT, glycerol-3-
phosphate acyltransferase; KPH, krill protein hydrolysate; ns, non-significant. 
 
The enterohepatic cycle begins at the canalicular membrane of the hepatocyte, where 
newly  synthesized  BAs  are  effluxed  into  the  canaliculus.  The  gene  expression  of 
Bsep/Abcb11, responsible for this transport, was down-regulated by KPH feeding (p = 0,002) 
(Fig. 5d). Further, the expression of the cognate transporter Abcb4, important for bile flow, 
was up-regulated by KPH feeding compared to the control (p = 0,004) (Fig. 5e). The mRNA 
levels of Abcc2 was also increased after KPH treatment (p = 0,02) (Fig. 5f), whereas the gene 
expression  of  Abcb1b  was  unaffected  (Fig.  5g).  No  differences  in  expression  of  the  BA 
importer  Slco1b2  were  found  (Fig.  5h),  whereas  the  expression  of  Slc10a1/Ntcp  was 
significantly  induced  (p  =  0,04)  (Fig.  5i).  Strikingly,  the  hepatic  Abcc3  expression  was 
induced 2.4 fold after KPH treatment (p = 0,02) (Fig. 5j), and the expression of Abcc4 almost 
11-fold (p = 0,002) (Fig. 5k). Functional Foods in Health and Disease 2013; 3(11):428-440                                                   Page 436 of 440 
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Figure 4. The effect of krill protein hydrolysate on plasma bile acid level  
Concentrations of plasma bile acid (BA) in fasted male C57BL/6 mice fed high-fat diets containing casein or 
KPH. Data are analyzed of pooled samples of four animals. BA, bile acid; KPH, krill protein hydrolysate. 
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 Figure  5.  The  effect  of  krill  protein  hydrolysate  on  expression  of  hepatic  genes  in  the 
enterohepatic cycle. Hepatic gene expression of (a) Cyp7α1, the rate limiting enzyme in bile acid (BA) Functional Foods in Health and Disease 2013; 3(11):428-440                                                   Page 437 of 440 
synthesis,  (b)  Baat,  responsible  for  conjugating  BAs  to  taurine  and  glycine,  and  of  (c)  Fxr,  important  in 
maintaining  the  BA  homeostasis,  in  high-fat  feeding  containing  casein  or  KPH.  Gene  expression  of  the 
canalucular exporters (d) Bsep/Abcb11, (e) Abcb4, (f) Abcc2,  (g) Abcb1b , the basolateral BA importers (h) 
Slco1b2 , (i) Slc19a1/Ntcp, and the basolateral BA exporters (j) Abcc3 and (k) Abcc4. Values were related to the 
reference gene 18S. Data are presented as mean ± SD, n = 6. * Denote significant difference: Mann-Whitney 
test (* = p < 0,05; ** = p < 0,01). Abcb1b, ATP-binding cassette, sub-family B, member 1b; Abcb4, ATP-
binding cassette sub-family B, member 4; ABCC2, ATP-binding cassette sub-family C, member 2; Abcc3, 
ATP-binding cassette, sub-family C, member 3; Abcc4, ATP-binding cassette, sub-family C, member 4; BA, 
bile  acid;  Baat,  bile  acid  coenzymeA:aminoacid  N-acyltransferase;  Bsep/Abcb11,  bile  salt  export  pump; 
Cyp7a1, cytochrome P450, family 7, sub-family A, polypeptide 1; Fxr, farnesoid X receptor; Slco1b2, solute 
carrier organic anion transporter family, member 1b2; Slc10a1/Ntcp , solute carrier family 10, member 1. 
 
DISCUSSION 
In the present study we have shown that a protein hydrolysate from krill elevated BA level, 
with a concomitant reduction in plasma TAG concentration in high-fat fed C57BL/6 mice. 
Moreover, induction of enzymes involved in mitochondrial fatty acid oxidation and genes 
encoding proteins involved in BA synthesis, transport and secretion was found. Previously, 
we reported that krill powder, consisting of both protein and fatty acids, increases liver lipid 
catabolism in TNFa transgenic mice fed a high-fat diet [13]. These results are interesting, as 
it  appears  that  the  bioactive  component  in  these  two  dietary  supplementations  lie  in  the 
protein fraction. The lipid lowering effect reported of KPH in the present study could be due 
to its amino acid composition. Studies have suggested that dietary proteins with low ratios of 
methionine/glycine and lysine/arginine have TAG-lowering effects [22].  As presented in 
table 2, the amino acid composition in the two diets are different, and characterized by a 
lower ratio of methionine/glycine and lysine/arginine in the KPH than in the casein control. 
Further, the data suggest that BA metabolism cross-talks with lipid metabolism. Indeed, 
BA administration has been shown to decrease plasma TAG concentration both in animals [1, 
2] and humans with hypertriacylglycerolemia [23-25]. Further, increased concentration of 
BAs most plausible induces transcription of Fxr target genes [26, 27]. FXR is not only an 
important regulator for BA metabolism, but also for lipid metabolism [28]. FXR-deficient 
mice  have  increased  synthesis  of  Apolipoprotein  B  (ApoB),  resulting  in  higher  TAG 
concentration  in  serum  and  liver  [20].  It  has  also  been  reported  that  BA  administration 
induces VLDL receptor transcription levels via a FXR-dependent mechanism [29], and this 
prevents  elevated  serum  and  liver  TAG  concentrations.  Finally,  BA  treatment  of  mice 
seemed to down-regulate lipogenesis via repression of SREBP-1C [2].  
We found no significant differences in hepatic activities of GPAT and FAS in KPH-
treated mice compared to controls. Though, KPH treatment increased the hepatic fatty acid 
catabolism  as  the  activity  of  the  PPARα  target  gene  CPT-2  was  increased.  Further,  the 
hepatic gene expression of Fxr was increased a 2-fold in the KPH treated mice compared to 
control. As FXR are reported to control plasma TAG levels by activating the PPARα gene 
[3], and PPARα is reported to induce genes encoding enzymes involved in mitochondrial 
fatty acid oxidation (reviewed in [4]), KPH regulation of BAs can possess the ability to 
modulate hepatic fatty acid oxidation, leading to reduced plasma TAG concentration. These 
results are in agreement with reported findings in rats by saithe Pollachius virens protein 
hydrolysate [30] and salmon protein hydrolysate [31]. 
The  increased  BA  concentration  could  be  due  to  different  factors,  including  BA 
synthesis. Indeed, the gene expression of Cyp7a1 tended to be induced in KPH-treated mice. 
The  gene  expression  of  the  BA  export  pump  Bsep/Abcb11  was  down-regulated,  and  the Functional Foods in Health and Disease 2013; 3(11):428-440                                                   Page 438 of 440 
phosphatidylcholine floppase  Aacb4,  which efflux the main components  of bile, was  up-
regulated  after  KPH  treatment.  The  expression  of  the  canalicular  exporter  Abcb1b  was 
however unchanged, whereas the expression of the BA exporter to the blood Abcc4 was 
induced by KPH feeding. Therefore, our data suggest that both higher BA synthesis and BA 
secretion to blood are underlying factors for the elevated plasma BA concentration. 
 
CONCLUSION 
Dietary treatment with KPH resulted in lower plasma concentration of TAGs and NEFAs, 
and elevated plasma level of BA compared to a casein control in high-fat fed mice. Further, 
induction of enzymes involved in mitochondrial fatty acid oxidation, and genes encoding 
proteins involved in BA synthesis, transport and secretion was found in the KPH-treated 
group. Altogether, it is plausible to suggest that lipid and BA metabolism can be modulated 
by  protein  hydrolysate  derived  from  krill,  and  that  increased  mitochondrial  fatty  acid 
oxidation and elevated BA concentration regulates plasma levels of TAGs and NEFAs. It is 
unclear  however,  whether  increased  plasma  BA  levels  are  a  cause  or  a  response  to 
hypotriacylglycerolemia. 
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